Caris Life Sciences and Ontada Partner to advance molecular research

Caris Life Sciences (Caris), a prominent next-generation AI TechBio firm and a leader in precision medicine, revealed a strategic and multifaceted partnership with Ontada, a company focused on oncology real-world evidence, clinical education, and point-of-care technologies, to promote molecular research and cancer treatment, improve the healthcare delivery system, and ultimately propel precision medicine by assisting life sciences firms in creating next-gen oncology therapies.

“Rooted in a commitment to rigorous science and cancer care, the collaboration between Caris and Ontada includes strategic pillars spanning the development and delivery of multimodal data solutions, innovative research strategies and data-driven practices to provide actionable cancer care intelligence,” said Caris president David Spetzler, MS, PhD, MBA. “By seamlessly integrating key entities of research, biopharma and patients, we collectively aim to revolutionize cancer research, drive innovation, advance precision medicine and improve patient outcomes.”

“By bringing together two of the most extensive clinical and genomic data sets in community oncology, we have developed a unique resource for life sciences companies. Our goal with this resource is to empower them to address complex questions, potentially leading to groundbreaking research and improved cancer care,” said Christine Davis, Ontada president. “Given the rapid evolution of oncology, this collaboration enables us to deliver insights more quickly, conduct more robust research and continue advancing precision care.”